Merck’s $1.3 Billion Gene-Silencing Deal: The Medicines That Could Change Patients’ Lives
Switching Off Disease Messages
Merck’s Silence Deal Targets Blood Cancer, With Heart Disease Also in Its Sights
Divesiran could reduce blood-removal procedures for a rare blood cancer, while a second experimental medicine targets an inherited cardiovascular risk factor.
Merck KGaA has agreed to buy British biotech Silence Therapeutics for approximately $1.3 billion, acquiring experimental medicines designed to interrupt the genetic messages cells use to make proteins.
The agreement, announced on 19 October 2026, puts a rare blood cancer treatment at the centre of a much broader scientific ambition. Silence’s lead medicine, divesiran, could help patients avoid repeated blood-removal procedures. Another candidate, zerlasiran, aims to lower a largely inherited blood particle linked to cardiovascular disease.
Neither medicine has established a cure. The strongest evidence concerns control of disease-related blood measurements and treatment burden. The next question is whether those improvements can become safe, durable benefits for patients.
What Merck Is Buying
Germany’s Merck KGaA is offering $20 in cash for each American depositary share of Silence. That represents a 130 per cent premium to the closing price on 16 October. The transaction values Silence’s equity at about $1.3 billion and its enterprise value at $1.1 billion. Those figures describe different financial measures of the same deal.
Completion is expected in the first quarter of 2027, subject to shareholder and regulatory approvals and court sanction. An agreed purchase is therefore still some distance from a completed takeover.
The buyer is the Darmstadt-based Merck KGaA, a separate company from America’s Merck & Co., known as MSD in many countries. That distinction matters when assessing the buyer’s strategy and existing medicines.
For Merck, the attraction extends beyond one drug. Silence brings a technology platform for designing treatments against selected genetic messages, alongside a pipeline that can be developed further if the science holds up.
How Gene Silencing Works
Genes contain instructions for making proteins. Cells copy those instructions into messenger RNA, which carries the information needed for protein production.
Silence develops short interfering RNA medicines, usually shortened to siRNA. These help the cell break down a chosen messenger RNA, reducing production of the corresponding protein. The treatment acts on the message rather than rewriting the DNA that produced it.
That separates this approach from gene editing. A gene-silencing injection may have a lasting effect, but it does not permanently correct an inherited genetic sequence.
Delivery is essential. Silence’s platform attaches sugar-based chemical tags to its medicines to help them enter liver cells. That makes the liver a useful production site to target, including when the harmful consequences appear elsewhere in the body.
It also sets a boundary on the promise. A system designed to reach liver cells cannot simply be assumed to deliver an effective treatment to every organ.
Divesiran: Reducing the Burden of a Rare Blood Cancer
The most immediate opportunity is polycythaemia vera, a blood cancer in which the bone marrow produces too many red blood cells. Patients may need repeated therapeutic blood draws, called phlebotomies, to keep the proportion of red cells in their blood under control.
Divesiran approaches that problem through iron regulation. It silences a liver gene called TMPRSS6, allowing levels of the iron-regulating hormone hepcidin to rise. That restricts the iron available to the bone marrow, limiting the material needed to produce excess red blood cells.
The aim is to control overproduction without relying so heavily on physically removing blood. For a patient whose life involves regular procedures, fewer visits could be a substantial benefit even without eliminating the cancer.
Silence announced results from its randomised phase 2 SANRECO trial on 10 August. The study included 48 patients dependent on phlebotomy. Across the divesiran groups, 88 per cent met the response measure, compared with 19 per cent receiving placebo.
Response meant avoiding phlebotomy while maintaining haematocrit, the proportion of blood made up of red cells, below 45 per cent during weeks 18 to 36. It did not mean that 88 per cent were cured.
The company reported no new safety findings, although two cases of mild anaemia were recorded. A small study cannot reliably establish uncommon risks. Silence’s announced plan was to begin a phase 3 trial in the first half of 2027, evaluating dosing every twelve weeks.
Zerlasiran: A Possible Route to Lower Heart Risk
Zerlasiran targets a different problem: elevated lipoprotein(a), commonly written as Lp(a). This blood particle is a cardiovascular risk factor whose concentration is largely determined by genetics.
The medicine aims to reduce production of a component needed to assemble the particle. Its promise is a way to address a risk factor that is difficult to change through familiar lifestyle measures alone.
A peer-reviewed phase 2 trial published in 2024 enrolled 178 people with established atherosclerotic cardiovascular disease and elevated Lp(a). Across three dosing regimens, zerlasiran reduced time-averaged levels by approximately 81 to 86 per cent relative to placebo over 36 weeks.
That finding demonstrates substantial biological activity. It does not demonstrate an equivalent reduction in heart attacks, strokes or deaths. A reduction in a blood marker is a different result from preventing an event that harms a patient.
If subsequent studies establish a favourable balance of clinical benefit and risk, the treatment could become a useful addition to cardiovascular prevention. It should not be described as repairing damage already caused by a heart attack or curing heart disease.
What Else Could the Technology Treat?
Silence’s published pipeline also identifies programmes aimed at abnormal blood fats, severe inherited high cholesterol, obesity and the complement system, part of the immune response.
These are separate development programmes. Success with divesiran would not establish that another RNA medicine works for obesity or an immune disorder. Each target requires evidence that reducing the relevant protein helps patients without causing unacceptable harm.
There are commercial uncertainties too. Silence disclosed that AstraZeneca would not pursue SLN312 beyond phase 1, with global rights returning to Silence after that phase. A pipeline entry therefore needs to be read alongside current development decisions, rather than treated as a medicine certain to reach market.
The platform’s potential lies in applying a shared design and delivery approach to different biological targets. The work of proving each treatment remains.
Could Any of These Medicines Cure Disease?
The evidence reviewed for this deal does not establish a cure for any of these conditions.
Divesiran aims to control excess red-cell production. Its mechanism does not itself remove the underlying cancerous cell population. Zerlasiran aims to suppress a cardiovascular risk factor while leaving the inherited instructions behind it intact.
Those limits do not make the treatments unimportant. Effective long-term control can reduce procedures, ease daily life and potentially prevent serious complications. But those benefits must be measured, and their duration established, rather than inferred from the word “genetic”.
Why the Deal Matters
The proposed takeover would place Silence’s programmes inside a company with greater resources for late-stage development and commercial delivery. Silence’s board says that scale could help accelerate divesiran’s progress. That is the intended benefit, rather than a guaranteed outcome of the purchase.
For British biotechnology, the agreement is evidence that a company’s research can attract a substantial international offer. It does not, by itself, establish future UK staffing, investment or manufacturing commitments.
For patients, the decisive milestone will be clinical. The planned phase 3 divesiran trial must test whether the encouraging response seen in 48 participants can be reproduced in a larger population with an acceptable safety profile. A $1.3 billion acquisition can finance that test; it cannot supply the answer.
Sources
Silence Therapeutics — Acquisition Agreement Announcement, 19 October 2026 — Company release distributed through Business Wire; offer terms, valuations and completion conditions.
Silence Therapeutics — Positive Phase 2 SANRECO Results, 10 August 2026 — Trial size, response definition, efficacy, safety and planned phase 3 development.
Nissen and Colleagues — Zerlasiran: A Phase 2 Randomized Clinical Trial, 2024 — Peer-reviewed evidence on Lp(a) reduction, dosing and the study’s measured outcomes.
Next Reads
Why Is CRISPR Such A Revolutionary Discovery — And How Far Could Gene Editing Go? — Understand how editing DNA differs from suppressing its messages.
Can The Human Heart Regrow Muscle? What The Evidence Actually Shows — The distinction between a biological finding and useful cardiac repair.
Cord-Blood T Cells Offer A Different Route To Cancer Immunotherapy — A different experimental cancer approach and the challenge of turning research into treatment.
